Test Price
1,200 AED✅ Home Collection Available
HLA Typing for Narcolepsy (DRB1*15, DQB1*06:02, DQA1*01:02) Test in UAE | 1,200 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity via ISO-accredited high-resolution sequencing in our central laboratory.
- VIP Mobile Phlebotomy: Temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Genetic Counselling: Post-test telephone consultation with a consultant medical geneticist to interpret results.
- Insurance Verification: Direct policy check via WhatsApp at +971 54 548 8731 with direct billing where applicable.
Test Overview & Methodology
The HLA Narcolepsy test detects the presence of high-risk alleles DRB1*15, DQB1*06:02, and DQA1*01:02 via sequencing-based typing (SBT), providing a definitive genetic susceptibility assessment for narcolepsy with or without cataplexy. This panel simultaneously interrogates three critical HLA loci at high resolution, offering superior specificity compared to single-locus or low-resolution methods.
| Feature | Our Test (HLA Narcolepsy Panel) | Standard HLA Typing (Single Locus) |
|---|---|---|
| Precision | High-resolution SBT for 3 critical loci simultaneously | Low-resolution or single-locus typing; misses key interactions |
| Methodology | Sequencing Based Typing (SBT) – Gold Standard | PCR-SSP or SSO (less definitive, lower resolution) |
| Speed | 10–12 days with ISO-accredited cold chain logistics | 12–15 days; variable quality control |
Physician Insight & Safety Protocols
Genetic susceptibility testing for narcolepsy through high-resolution HLA typing provides valuable risk stratification, yet it must always be correlated with clinical history and objective sleep studies. A positive finding for DQB1*06:02 indicates a significantly elevated predisposition but does not alone confirm the disorder. Our role is to ensure patients receive comprehensive pre- and post-test counselling, helping them understand the implications and next steps in their diagnostic journey.
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Clinical Safety & Medical Liability
All procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring patient safety and informed consent. The treating physician retains full clinical responsibility for correlating genetic findings with the patient's overall health status and sleep study results. Patients are advised not to alter or discontinue any prescribed medications unless explicitly directed by their doctor.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Not appropriate for patients who have had a blood transfusion or hematopoietic stem cell transplant within 90 days, or those on high-dose immunosuppressants that may alter leukocyte count.
- Emergency Red Flags: Sudden onset of severe cataplexy causing falls; loss of consciousness; hallucinations with autonomic instability (profuse sweating, tachycardia). These warrant immediate emergency evaluation regardless of genetic results.
Patient FAQ & Clinical Guidance
1. What does a positive HLA DQB1*06:02 result mean for narcolepsy?
A positive DQB1*06:02 result signals a markedly elevated genetic risk for narcolepsy with cataplexy, necessitating clinical correlation. Over 95% of patients with narcolepsy type 1 carry this allele. However, confirmatory sleep studies — polysomnography and the Multiple Sleep Latency Test — remain essential for definitive diagnosis. False positives are exceptionally rare with high-resolution SBT methodology.
2. How is the test performed and what sample type is required?
A 4 mL whole blood sample in an EDTA (lavender-top) or ACD (yellow-top) tube is required; no fasting is necessary. Our certified phlebotomist collects the sample during a scheduled home visit between 8 AM and 11 PM. The specimen must be maintained at 2–8°C and never frozen to preserve leukocyte integrity. Temperature-controlled courier transport ensures cold-chain compliance to our ISO 9001:2015 accredited central laboratory.
3. Is this test covered by health insurance in the UAE?
UAE insurance plans typically cover narcolepsy HLA testing when prescribed by a neurologist; we verify coverage via WhatsApp. Leading providers including Daman and Oman Insurance often reimburse or directly settle claims when pre-authorisation is obtained. Our team reviews your policy within minutes and coordinates direct billing where applicable, minimising out-of-pocket expenses. Contact us at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This laboratory operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. ISO 9001:2015 Certified. DHA Facility License: 1143. DNA Labs UAE is committed to the highest standards of data security and patient confidentiality.
Clinical & Logistical Metadata
| Test Name | HLA Typing for Narcolepsy (DRB1*15, DQB1*06:02, DQA1*01:02) |
| Price (AED) | 1,200 AED |
| Turnaround Time | 10–12 Business Days |
| Sample Type / Matrix | 4 mL Whole Blood (EDTA or ACD Tube) |
| Methodology Used | Sequencing-Based Typing (SBT) – High-Resolution HLA Typing |
| ICD-10-CM Code | Z13.89, G47.411, G47.419 |
| LOINC Code | 20462-8, 20459-4, 20456-0 |
| DHA Facility License & Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians